📣 VC round data is live. Check it out!

Giant Biogene Valuation Multiples

Discover revenue and EBITDA valuation multiples for Giant Biogene and similar public comparables like GSK India, Proya Cosmetics, Hengan Group, Unilever Indonesia and more.

Giant Biogene Overview

About Giant Biogene

Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.


Founded

2021

HQ

China

Employees

1.8K

Website

xajuzi.com

Financials (LTM)

Revenue: $842M
EBITDA: $337M

EV

$3B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Giant Biogene Financials

Giant Biogene reported last 12-month revenue of $842M and EBITDA of $337M.

In the same LTM period, Giant Biogene generated $673M in gross profit, $337M in EBITDA, and $282M in net income.

Revenue (LTM)


Giant Biogene P&L

In the most recent fiscal year, Giant Biogene reported revenue of $816M and EBITDA of $360M.

Giant Biogene is profitable as of last fiscal year, with gross margin of 80%, EBITDA margin of 44%, and net margin of 35%.

See analyst estimates for Giant Biogene
LTMLast FY202320242025202620272028
Revenue$842M$816M$521M$819M$816M
Gross Profit$673M$655M$436M$672M$655M
Gross Margin80%80%84%82%80%
EBITDA$337M$360M$263M$371M$360M
EBITDA Margin40%44%50%45%44%
EBIT Margin38%39%47%42%39%
Net Profit$282M$283M$215M$305M$283M
Net Margin34%35%41%37%35%

Financial data powered by Morningstar, Inc.

Giant Biogene Stock Performance

Giant Biogene has current market cap of $4B, and enterprise value of $3B.

Market Cap Evolution


Giant Biogene's stock price is $3.69.

Giant Biogene share price decreased by 3.9% in the last 30 days, and by 49.9% in the last year.

Giant Biogene has an EPS (earnings per share) of $0.27.

See more trading valuation data for Giant Biogene
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3B$4B-2.0%-3.9%5.0%-49.9%$0.27

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Giant Biogene Valuation Multiples

Giant Biogene trades at 3.2x EV/Revenue multiple, and 8.0x EV/EBITDA.

See NTM and 2027E valuation multiples for Giant Biogene

EV / Revenue (LTM)


Giant Biogene Financial Valuation Multiples

As of June 3, 2026, Giant Biogene has market cap of $4B and EV of $3B.

Giant Biogene has a P/E ratio of 13.9x.

LTMLast FY202320242025202620272028
EV/Revenue3.2x3.3x5.2x3.3x3.3x
EV/EBITDA8.0x7.5x10.2x7.3x7.5x
EV/EBIT8.4x8.5x10.9x7.9x8.5x
EV/Gross Profit4.0x4.1x6.2x4.0x4.1x
P/E13.9x13.8x18.2x12.8x13.8x
EV/FCF11.3x11.0x12.8x10.1x13.5x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Giant Biogene Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Giant Biogene Margins & Growth Rates

Giant Biogene grew revenue by 10% but EBITDA decreased by 4% in the last fiscal year.

In the most recent fiscal year, Giant Biogene reported gross margin of 80%, EBITDA margin of 44%, and net margin of 35%.

See estimated margins and future growth rates for Giant Biogene

Giant Biogene Margins

Last FY202420252026202720282029
Gross Margin80%82%80%79%
EBITDA Margin44%45%44%38%
EBIT Margin39%42%39%36%
Net Margin35%37%35%32%
FCF Margin30%32%24%25%

Giant Biogene Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth10%57%(0%)10%
Gross Profit Growth9%54%(2%)9%
EBITDA Growth(4%)41%(3%)(4%)
EBIT Growth2%39%(7%)2%
Net Profit Growth2%42%(7%)2%
FCF Growth(7%)26%(25%)14%

Data powered by FactSet, Inc. and Morningstar, Inc.

Giant Biogene Operational KPIs

Giant Biogene's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.

Giant Biogene's Rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Giant Biogene's Rule of X is 63% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Giant Biogene
LTMLast FY202320242025202620272028
Rule of 4053%48%---
Bessemer Rule of X72%63%---
Revenue per Employee-$0.5M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue38%37%33%36%37%
G&A Expenses to Revenue4%4%3%3%3%
R&D Expenses to Revenue2%2%2%2%2%
Opex to Revenue-42%36%40%42%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Giant Biogene Competitors

Giant Biogene competitors include GSK India, Proya Cosmetics, Hengan Group, Unilever Indonesia, Fielmann Group, AmorePacific, Rohto Pharmaceutical, Procter & Gamble Hygiene, e.l.f. Beauty and Inter Parfums.

Most Giant Biogene public comparables operate across Health & Beauty.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
GSK India9.0x8.8x23.2x25.6x
Proya Cosmetics2.0x2.0x10.7x10.8x
Hengan Group1.0x1.0x5.3x5.8x
Unilever Indonesia1.7x1.7x11.0x10.7x
Fielmann Group1.8x1.7x7.5x7.4x
AmorePacific1.4x1.3x9.5x9.2x
Rohto Pharmaceutical1.6x1.4x8.8x8.4x
Procter & Gamble Hygiene6.8x6.7x24.6x24.8x

This data is available for Pro users. Sign up to see all Giant Biogene competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Giant Biogene

When was Giant Biogene founded?Giant Biogene was founded in 2021.
Where is Giant Biogene headquartered?Giant Biogene is headquartered in China.
How many employees does Giant Biogene have?As of today, Giant Biogene has over 1K employees.
Who is the CEO of Giant Biogene?Giant Biogene's CEO is Jianya Yan.
Is Giant Biogene publicly listed?Yes, Giant Biogene is a public company listed on HKEX.
What is the stock symbol of Giant Biogene?Giant Biogene trades under 02367 ticker.
When did Giant Biogene go public?Giant Biogene went public in 2022.
Who are competitors of Giant Biogene?Giant Biogene main competitors include GSK India, Proya Cosmetics, Hengan Group, Unilever Indonesia, Fielmann Group, AmorePacific, Rohto Pharmaceutical, Procter & Gamble Hygiene, e.l.f. Beauty, Inter Parfums.
What is the current market cap of Giant Biogene?Giant Biogene's current market cap is $4B.
What is the current revenue of Giant Biogene?Giant Biogene's last 12 months revenue is $842M.
What is the current revenue growth of Giant Biogene?Giant Biogene revenue growth (NTM/LTM) is 13%.
What is the current EV/Revenue multiple of Giant Biogene?Current revenue multiple of Giant Biogene is 3.2x.
What is the current EBITDA of Giant Biogene?Giant Biogene's last 12 months EBITDA is $337M.
What is Giant Biogene's EBITDA margin?Giant Biogene's last 12 months EBITDA margin is 40%.
What is the current EV/EBITDA multiple of Giant Biogene?Current EBITDA multiple of Giant Biogene is 8.0x.
What is the current FCF of Giant Biogene?Giant Biogene's last 12 months FCF is $238M.
What is Giant Biogene's FCF margin?Giant Biogene's last 12 months FCF margin is 28%.
What is the current EV/FCF multiple of Giant Biogene?Current FCF multiple of Giant Biogene is 11.3x.
How many companies Giant Biogene has acquired to date?Giant Biogene hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Giant Biogene has invested to date?Giant Biogene hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Giant Biogene

Lists including Giant Biogene

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial